<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; benefits</title>
	<atom:link href="http://www.tapanray.in/tag/benefits/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Leverage Increased Focus On ‘Self-Care’ For Better Patient Outcomes</title>
		<link>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leverage-increased-focus-on-self-care-for-better-patient-outcomes</link>
		<comments>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/#comments</comments>
		<pubDate>Mon, 24 Jan 2022 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infectious]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[messaging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[non-infectious]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[ovid-19]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-care]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10640</guid>
		<description><![CDATA[‘People have been practicing self-care for thousands of years. Now an increase in self-care interventions is shifting the way health care is perceived, understood, and accessed, and adding to the many medicines, diagnostics, and technologies available for people to use &#8230; <a href="http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Essential ‘Acrobatic Feat’ Remains Relevant Even In Digital Pharma World</title>
		<link>http://www.tapanray.in/an-essential-acrobatic-feat-remains-relevant-even-in-digital-pharma-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-essential-acrobatic-feat-remains-relevant-even-in-digital-pharma-world</link>
		<comments>http://www.tapanray.in/an-essential-acrobatic-feat-remains-relevant-even-in-digital-pharma-world/#comments</comments>
		<pubDate>Mon, 17 Feb 2020 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[' lifting his eyes to the hills']]></category>
		<category><![CDATA['keep his nose to the grindstone']]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[extrinsic]]></category>
		<category><![CDATA[features]]></category>
		<category><![CDATA[intrinsic]]></category>
		<category><![CDATA[Manager]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[measurement]]></category>
		<category><![CDATA[parameters]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment experience]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[‘Acrobatic Feat’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9878</guid>
		<description><![CDATA[“A manager must, so to speak, keep his nose to the grindstone while lifting his eyes to the hills — quite an acrobatic feat!” This profound statement was articulated by the Management Guru of all-time – Peter F. Drucker, in his book &#8230; <a href="http://www.tapanray.in/an-essential-acrobatic-feat-remains-relevant-even-in-digital-pharma-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-essential-acrobatic-feat-remains-relevant-even-in-digital-pharma-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Affordable Access To Quality Healthcare in India, Invest Where The Mouth Is</title>
		<link>http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is</link>
		<comments>http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/#comments</comments>
		<pubDate>Mon, 25 Mar 2019 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB-NHPS]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Ayushman Bharat Program]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[hospitalization]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[invest]]></category>
		<category><![CDATA[Modicare]]></category>
		<category><![CDATA[National Health Protection Scheme]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[where the mouth is]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9454</guid>
		<description><![CDATA[On September 25, 2018, well-hyped Ayushman Bharat &#8211; National Health Protection Scheme (AB-NHPS), touted as the largest health scheme in the world, was launched in India. Prior to its launch, while announcing the scheme on August 15, 2018 from the &#8230; <a href="http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Interesting demand: No Price Control For OTC Drugs</title>
		<link>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-interesting-demand-no-price-control-for-otc-drugs</link>
		<comments>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/#comments</comments>
		<pubDate>Mon, 19 Nov 2018 00:00:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[decontrol]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[switch]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9286</guid>
		<description><![CDATA[Since over a decade, some pharma trade organizations operating in India, have been advocating for a separate regulatory policy for ‘Over The Counter (OTC)’ drugs, which can be legally sold without any medical prescriptions. Such a new policy initiative, if taken by &#8230; <a href="http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Interesting Link: Productivity At Work and Employee Fitness (In 2 Parts)</title>
		<link>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts</link>
		<comments>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/#comments</comments>
		<pubDate>Mon, 16 Apr 2018 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[exercises]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[VUCA]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8929</guid>
		<description><![CDATA[Part 1: Physical Fitness Today’s work environment is much more challenging than ever before. The challenge is undoubtedly multi-factorial. Many of these are external – mostly related to increasing complex, and difficult to fathom uncertainties and surprises in the overall &#8230; <a href="http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Humongous Pharma Corruption: China Ups The Ante&#8230;and India?</title>
		<link>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=humongous-pharma-corruption-china-ups-the-ante-and-india</link>
		<comments>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/#comments</comments>
		<pubDate>Mon, 23 Sep 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alcon]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[Apco]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[behind]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[biopharmaceuticals]]></category>
		<category><![CDATA[bribers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chases]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conducts]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[crack]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[Gan]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Lee]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[remain]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[Sino]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[Values]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3696</guid>
		<description><![CDATA[In the &#8216;pharma bribery&#8217; related scandal in China, many postulated that the Chinese Government has cracked down selectively on Multinational Corporations (MNCs) to extend unfair business advantages for its local players. Media reports of September 2013 indicate that in all &#8230; <a href="http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
